Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Somnolence19.02.05.003; 17.02.04.0060.005262%
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.0200.001462%
Stillbirth18.01.02.002; 08.04.01.006--Not Available
Stress19.06.02.0040.000877%Not Available
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.0040.000877%
Swelling08.01.03.0150.000585%Not Available
Swelling face23.04.01.018; 10.01.05.0180.000877%Not Available
Swollen tongue23.04.01.014; 10.01.05.015; 07.14.02.0030.000585%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.000585%
Tachycardia02.03.02.0070.000585%Not Available
Throat irritation22.02.05.013; 07.05.03.0040.000585%Not Available
Throat tightness22.02.05.015; 19.01.02.0050.000585%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000585%
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.0070.000585%Not Available
Tremor17.01.06.0020.001462%
Urinary retention20.02.02.0110.000585%
Urticaria23.04.02.001; 10.01.06.0010.002631%
Vasodilatation23.06.05.006; 24.03.02.0030.000585%Not Available
Ventricular extrasystoles02.03.04.0070.000585%Not Available
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred06.02.06.007; 17.17.01.0100.000877%
Visual impairment06.02.06.008--Not Available
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.001169%
Musculoskeletal disorder15.03.01.0040.000585%Not Available
Hypoacusis04.02.01.0060.000585%
Contusion24.07.06.001; 23.03.11.002; 15.03.01.008; 12.01.06.0010.000585%
Generalised erythema23.03.06.0080.001462%Not Available
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages